[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-338012-105":59,"doc-detail-338012-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","enhancing-cart-cells-function-role-of-immunomodulators-in-cancer-immunotherapy","Enhancing CART cells function - role of immunomodulators in cancer immunotherapy","","CAR T-cell therapy is a promising cancer immunotherapy, yet performance barriers reduce its optimal activity. CAR T cells may become exhausted, generate toxic reactions, and often fail to achieve desired outcomes in solid tumors. To address these limitations, supplementary immunomodulators are evaluated, including phytochemicals, FDA-approved targeted drugs, and interleukins. Reported literature suggests that appropriate combinations of immunotherapy, immunomodulators, and conventional cancer treatments may yield improved anti-cancer results in future applications.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/enhancing-cart-cells-function-role-of-immunomodulators-in-cancer-immunotherapy/338012/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/enhancing-cart-cells-function-role-of-immunomodulators-in-cancer-immunotherapy/338012.png","ImageObject",300,407,{"name":92,"@type":93},"Oliver","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-10-23","2026-09-21",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is CAR T-cell therapy not always effective in solid tumors?","Question",{"text":112,"@type":113},"Solid tumors can hinder CAR T-cell infiltration, and targeted antigens may not yield the desired therapeutic outcomes. Tumors may also resist CAR T targeting, and CAR T cells can become exhausted during the process.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What kinds of immunomodulators are considered to improve CAR T-cell therapy?",{"text":117,"@type":113},"The document reviews immunomodulators including phytochemicals, FDA-approved targeted drugs, and interleukins. These agents are studied for their potential to boost CAR T-cell efficiency and outcomes.",{"name":119,"@type":110,"acceptedAnswer":120},"What major side effects of CAR T-cell therapy are highlighted?",{"text":121,"@type":113},"Side effects with incidence above 20% include hypogammaglobulinemia, sepsis, encephalopathy, bleeding episodes, coagulopathy, hypotension, tachycardia, viral infectious disorders, and hypoxia.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},338012,1791436742,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":133,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":139,"language":140,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":67,"update_tm":144,"read_time":145,"preview_page_count":19,"preview_urls":146},8796095461610,"https://ap-avatar.wpscdn.com/davatar_276721f389ce27ea32af1340a28f341c","Clinical and Experimental Medicine (2024) 24:180 [https://doi.org/10.1007/s10238-024-01442-9](https://doi.org/10.1007/s10238-024-01442-9)  \nEnhancing CART cells function: role of immunomodulators in cancer immunotherapy  \nMaheen Rehman1 · Ariba Qaiser1 · Hassan Sardar Khan1 · Sobia Manzoor1 · Javed Ashraf2,3  \nReceived: 20 June 2024 / Accepted: 18 July 2024 / Published online: 6 August 2024 © The Author(s), under exclusive licence to Springer Nature Switzerland AG 2024  \nAbstract  \nCAR T-cell therapy is a promising immunotherapy, providing successful results for cancer patients who are unresponsive to standard and traditional therapeutic approaches. However, there are limiting factors which create a hurdle in the therapy performing its role optimally. CAR T cells get exhausted, produce active antitumor responses, and might even produce toxic reactions. Specifically, in the case of solid tumors, chimeric antigen receptor T (CAR-T) cells fail to produce the desired outcomes. Then, the need to use supplementary agents such as immune system modifying immunomodulatory agents comes into play. A series of the literature was studied to evaluate the role of immunomodulators including a phytochemical, Food and Drug Administration (FDA)-approved targeted drugs, and ILs in support of their achievements in boosting the efficiency of CAR-T cell therapy. Some of the most promising out of them are reported in this article. It is expected that by using the right combinations of immunotherapy, immunomodulators, and traditional cancer treatments, the best possible cancer defying results may be produced in the future.  \nKeywords CAR T cells · Combinatory therapy · Immunotherapy · Immunomodulators · Cancer  \nAbbreviations  \nCAIX Carbonic anhydrase IX  \nCAR Chimeric antigen receptor  \nCD3ζ Cluster of differentiation 3 zeta  \nCoS Costimulatory domains  \nCRS Cytokine release syndrome  \nFcRγ Fragment crystallizable receptor gamma  \nGMCSF Granulocyte monocyte colony-stimulating  \nfactor GPC-3 Glypican-3  \nHGC Human gastric carcinoma  \nICANS Immune effector cell-associated neurotoxic  \nity syndrome IFN Interferon  \nIL Interleukin  \n* Javed Ashraf  \nJaveda@student.uef.fi; Javed.ashraf@riphah.edu.pk  \n1 Molecular Virology Lab, Atta-Ur-Rahman School of Applied Biosciences, National University of Sciences and Technology, Islamabad, Pakistan  \n2 Institute of Dentistry, University of Eastern Finland, Kuopio, Finland  \n3 Riphah International University, Islamabad, Pakistan  \nITAMs  \nMDSCs  \nmTOR  \nnM  \nPBMCs  \nPDGFR  \nPD-L1  \nPI3K/AKT  \nRCC  \nSFN  \nTAA  \nTCR  \nTME  \nTRUCKs  \nT-regs VH  \nVL  \nZAP70  \nImmune receptor tyrosine-based activation motifs  \nMyeloid-derived suppressor cells Mechanistic target of rapamycin Nanomolar  \nPeripheral blood mononuclear cells Platelet-derived growth factor receptor Programmed death ligand 1  \nPhosphoinositide 3-kinase/protein kinase B  \nRenal carcinoma Sulforaphane  \nTumor-associated antigen T-cell receptor  \nTumor microenvironment  \nT cells redirected for universal cytokinemediated killing  \nT regulatory cells Variable heavy chain  \nVariable light chain  \nZeta chain-associated protein kinase  \nIntroduction  \nChimeric antigen receptors are synthetically designed recombinant receptors. They bind to specific antigens and perform T-cell activating functions. CARs are living drugs that have a great aptitude for cancer immunotherapy [1] . Chimeric antigen receptor T cells (CAR-T cells) are T cells that are expanded after stimulation and have genetic modifications. T cells are extracted from a donor’s blood and after their conversion into CAR T cells, they are infused into the subjects of research, clinical trial, or a patient undergoing CAR T-cell immunotherapy [2] . Immunotherapy of the CAR T type may be autologous or allogenic [2 , 3] . The genetically modified T cells begin to express achimeric antigen receptor (CAR) which targets an antigen of neoplastic origin [4] . CAR-T cell therapy has achieved the status of a hallmark ther","cbCaidMfbbc2GlYI","https://ap.wps.com/l/cbCaidMfbbc2GlYI","pdf",1525476,14,"English","# Introduction\n## CAR T cells and their therapeutic design\n## Limitations and adverse effects\n# Immunomodulators and combinatory strategies\n## Rationale for enhancing CAR T-cell action","[{\"question\":\"Why is CAR T-cell therapy not always effective in solid tumors?\",\"answer\":\"Solid tumors can hinder CAR T-cell infiltration, and targeted antigens may not yield the desired therapeutic outcomes. Tumors may also resist CAR T targeting, and CAR T cells can become exhausted during the process.\"},{\"question\":\"What kinds of immunomodulators are considered to improve CAR T-cell therapy?\",\"answer\":\"The document reviews immunomodulators including phytochemicals, FDA-approved targeted drugs, and interleukins. These agents are studied for their potential to boost CAR T-cell efficiency and outcomes.\"},{\"question\":\"What major side effects of CAR T-cell therapy are highlighted?\",\"answer\":\"Side effects with incidence above 20% include hypogammaglobulinemia, sepsis, encephalopathy, bleeding episodes, coagulopathy, hypotension, tachycardia, viral infectious disorders, and hypoxia.\"}]","Enhancing CART cells function - role of immunomodulators in cancer immunotherapy | PDF",1790021569,35,[147,151,155,159],{"page_no":8,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/a19460ba91a3fc8960b5dcfddbe0e3bb.webp",983,1305,{"page_no":14,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/1302283276e8a87e4bf755ee08c1085f.webp",982,1304,{"page_no":81,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/4267407bf2d0df7dc320b73f444f8416.webp",981,1303,{"page_no":19,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/b6109aed9bc0bcd26ed3e34ae5e3c78e.webp",980,1301]